Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 27 August 2009, Vol. 114, No. 9, pp. 1820-1830.
Prepublished online as a Blood First Edition Paper on July 1, 2009; DOI 10.1182/blood-2009-02-206573.


This Article
Right arrow Full Text (PDF)
Right arrow Supplemental Figures
Right arrow All Versions of this Article:
blood-2009-02-206573v1
114/9/1820    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Google Scholar
Right arrow Articles by Wood, A. D.
Right arrow Articles by Gottgens, B.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wood, A. D.
Right arrow Articles by Gottgens, B.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Next Article next article arrow

Submitted February 23, 2009
Accepted June 14, 2009

Id1 promotes expansion and survival of primary erythroid cells and is a target of JAK2V617F-STAT5 signalling

Andrew D. Wood, Edwin Chen, Ian J. Donaldson, Shilpa Hattangadi, Karly A. Burke, Mark A. Dawson, Diego Miranda-Saavedra, Harvey F. Lodish, Anthony R. Green, and Berthold Gottgens*

Department of Hematology, Cambridge Institute for Medical Research, Addenbrooke's Hospital, Cambridge, United Kingdom
Faculty of Life Sciences, University of Manchester, Manchester, United Kingdom
Whitehead Institute for Biomedical Research, Cambridge, MA, United States

* Corresponding author; email: bg200{at}cam.ac.uk.

The discovery of JAK2V617F as an acquired mutation in the majority of patients with myeloproliferative disorders (MPDs) and the key role of the JAK2-STAT5 signalling cascade in normal hematopoiesis has focussed attention on the downstream transcriptional targets of STAT5. Despite evidence of its vital role in normal erythropoiesis and its ability to recapitulate many of the features of myeloid malignancies, including the MPDs, few functionally validated targets of STAT5 have been described. Here we used a combination of comparative genomics and chromatin immunoprecipitation assays to identify ID1 as a novel target of the JAK2-STAT5 signalling axis in erythroid cells. STAT5 binds and transactivates a downstream enhancer of ID1 and ID1 expression levels correlate with the JAK2V617F mutation in both retrovirally transfected fetal liver cells and polycythemia vera (PV) patients. Knockdown and overexpression studies in a well-characterised erythroid differentiation assay from primary murine fetal liver cells demonstrated a survival-promoting action of ID1. This hitherto unrecognised function implicates ID1 in the expansion of erythroblasts during terminal differentiation and suggests that ID1 plays an important role in the pathogenesis of PV. Furthermore, our findings contribute to an increasing body of evidence implicating ID proteins in a wider range of cellular functions than initially appreciated.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020